Targets › GSK3B
3 programs from 3 companies in 15 trials: 7 Phase 2, 4 Phase 1, 3 Phase 4, 1 Phase 3; Neurology, Oncology, Cardiovascular; next expected readout Dec 2026.
Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), EIF2B, CTNNB1/beta-catenin, APC, AXIN1, DPYSL2/CRMP2, JUN, NFATC1/NFATC, MAPT/TAU and MACF1. Requires primed phosphorylation of the majority of its substrates. (UniProt, P49841)
Open in Phaseline: the race on GSK3B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AMO Pharma | Tideglusib Glycogen synthase kinase-3 beta inhibitor | GSK3B | Phase 2 | Congenital Myotonic Dystrophy; Arrhythmogenic Cardiomyopathy | Dec 2026 |
| Actuate Therapeutics | Elraglusib (ING-41) Glycogen synthase kinase-3 beta inhibitor | GSK3B | Phase 2 | Cancer; Pancreatic Adenocarcinoma; Salivary Gland Cancer | – |
| Alzamend Neuro | Lithium Carbonate (AL001) Inositol-1(or 4)-monophosphatase 1 inhibitor; Glycogen synthase kinase-3 inhibitor | IMPA1, GSK3A, GSK3B | Phase 1 | Bipolar I Disorder; Healthy; Bipolar II Disorder; Depression, Bipolar … | Dec 2026 |
Pancreatic Adenocarcinoma (2) Congenital Myotonic Dystrophy (1) Arrhythmogenic Cardiomyopathy (1) Bipolar I Disorder (1) Healthy (1) Bipolar II Disorder (1) Depression, Bipolar (1) Bipolar Depression (1) Cornelia De Lange Syndrome (1) Cognitive Impairment (1) Parkinson Disease (1) Proven Pathogenic or Probably Pathogenic TBR1 Variant (1)
small molecule (2), mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.